Legend Biotech Corp (NASDAQ: LEGN) Chief Executive Officer Huang Ying executed a transaction on June 25, 2026, involving the sale of 5,566 ordinary shares. The total monetary value of this transaction was recorded at $82,265. The execution of the sale occurred at a weighted average price of $14.78 per ordinary share. The price range for these ordinary shares during the transaction spanned from $14.065 to $14.99. These ordinary shares are representative of American Depositary Shares (ADSs), with each ADS corresponding to two ordinary shares. The price range for the corresponding ADSs in this transaction extended from $28.13 to $29.98. The stock currently trades at $29.39, reflecting a 35% gain over the past six months.
The sale was executed to satisfy withholding tax obligations upon the vesting of restricted share units. Following this transaction, Mr. Huang directly holds 241,872 ordinary shares in Legend Biotech. The biotech company has demonstrated robust revenue growth of 56% over the last twelve months. According to InvestingPro analysis, the stock appears undervalued relative to its Fair Value. Investors seeking deeper insights can access comprehensive analysis and additional ProTips on the platform.
In other recent news, Legend Biotech Corporation announced the pricing of an underwritten public offering of 7.7 million American Depositary Shares at $29.35 per ADS, totaling approximately $226 million. This offering follows the company’s earlier announcement of a $225 million public share offering, indicating a strategic move to raise capital. Legend Biotech has also reported promising results from a Phase 1 trial of its investigational in vivo CAR-T cell therapy, LB2501, targeting CD19 and CD20 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The trial showed a 100% objective response rate and an 83.3% complete response rate at the higher dose level, with ongoing responses at the data cutoff.
Meanwhile, Calidi Biotherapeutics has appointed Corsee Sanders, Ph.D., to its Board of Directors as an independent director. Sanders brings over 30 years of experience in biopharmaceutical development and clinical operations, having previously served as a strategic advisor to Celgene’s Chief Medical Officer. These developments reflect significant strategic and operational changes within these companies.